Correlation Between CT Features of Active Tuberculosis and Residual Metabolic Activity on End-of-Treatment FDG PET/CT in Patients Treated for Pulmonary Tuberculosis.

FDG PET/CT HIV infection computed tomography end-of-treatment pulmonary tuberculosis residual metabolic activity

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2022
Historique:
received: 08 10 2021
accepted: 27 01 2022
entrez: 17 3 2022
pubmed: 18 3 2022
medline: 18 3 2022
Statut: epublish

Résumé

Patients who complete a standard course of anti-tuberculous treatment (ATT) for pulmonary tuberculosis and are declared cured according to the current standard of care commonly have residual metabolic activity (RMA) in their lungs on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PER/CT) imaging. RMA seen in this setting has been shown to be associated with relapse of tuberculosis. The routine clinical use of FDG PET/CT imaging for treatment response assessment in tuberculosis is hindered by cost and availability. CT is a more readily available imaging modality. We sought to determine the association between CT features suggestive of active tuberculosis and RMA on FDG PET/CT obtained in patients who completed a standard course of ATT for pulmonary tuberculosis. We prospectively recruited patients who completed a standard course of ATT and declared cured based on negative sputum culture. All patients had FDG PET/CT within 2 weeks of completing ATT. We determined the presence of RMA on FDG PET images. Among the various lung changes seen on CT, we considered the presence of lung nodule, consolidation, micronodules in tree-in-bud pattern, FDG-avid chest nodes, and pleural effusion as suggestive of active tuberculosis. We determine the association between the presence of RMA on FDG PET and the CT features of active tuberculosis. We include 75 patients with a mean age of 36.09 ± 10.49 years. Forty-one patients (54.67%) had RMA on their FDG PET/CT while 34 patients (45.33%) achieved complete metabolic response to ATT. There was a significant association between four of the five CT features of active disease,

Identifiants

pubmed: 35295606
doi: 10.3389/fmed.2022.791653
pmc: PMC8920557
doi:

Types de publication

Journal Article

Langues

eng

Pagination

791653

Informations de copyright

Copyright © 2022 Lawal, Mokoala, Mathebula, Moagi, Popoola, Moeketsi, Nchabeleng, Hikuam, Ellner, Hatherill, Fourie and Sathekge.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

PLoS One. 2021 May 3;16(5):e0250616
pubmed: 33939723
N Engl J Med. 2021 May 6;384(18):1705-1718
pubmed: 33951360
Semin Nucl Med. 2018 Mar;48(2):108-130
pubmed: 29452616
J Bacteriol. 2000 Nov;182(22):6358-65
pubmed: 11053379
Ann Thorac Surg. 2011 Jul;92(1):290-5
pubmed: 21549347
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195
pubmed: 27516382
N Engl J Med. 2014 Oct 23;371(17):1577-87
pubmed: 25196020
Lancet Oncol. 2021 Apr;22(4):e136-e172
pubmed: 33676609
Nat Med. 2016 Oct;22(10):1094-1100
pubmed: 27595324
Cochrane Database Syst Rev. 2019 Dec 12;12:CD012918
pubmed: 31828771
Epidemiol Infect. 1997 Oct;119(2):183-201
pubmed: 9363017
Nucl Med Commun. 2018 Nov;39(11):1005-1012
pubmed: 30198974
Nuklearmedizin. 2018 Sep;57(5):190-197
pubmed: 30267401
Trop Med Int Health. 2020 Apr;25(4):483-495
pubmed: 31944502
J Nucl Med. 2011 Jun;52(6):880-5
pubmed: 21571788
Ecancermedicalscience. 2020 Aug 28;14:1093
pubmed: 33014135
Infect Drug Resist. 2021 Mar 18;14:1115-1128
pubmed: 33776457
Int J Tuberc Lung Dis. 2012 Sep;16(9):1180-5
pubmed: 22794271
PLoS One. 2020 Apr 17;15(4):e0231537
pubmed: 32302345
PLoS One. 2019 Apr 18;14(4):e0215412
pubmed: 30998728
Rev Soc Bras Med Trop. 2017 Jan-Feb;50(1):9-18
pubmed: 28327797
Arch Intern Med. 2003 May 12;163(9):1009-21
pubmed: 12742798
Semin Nucl Med. 2018 Mar;48(2):166-181
pubmed: 29452619
J Nucl Med. 2020 Mar;61(3):412-417
pubmed: 31451489
Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1184-90
pubmed: 22526957

Auteurs

Ismaheel O Lawal (IO)

Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa.

Kgomotso M G Mokoala (KMG)

Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa.

Matsontso Mathebula (M)

Department of Medical Microbiology and MeCRU, Sefako Makgatho University of Medical Science, Pretoria, South Africa.

Ingrid Moagi (I)

Department of Medical Microbiology and MeCRU, Sefako Makgatho University of Medical Science, Pretoria, South Africa.

Gbenga O Popoola (GO)

Department of Epidemiology and Community Health, University of Ilorin, Ilorin, Nigeria.

Nontando Moeketsi (N)

Department of Medical Microbiology and MeCRU, Sefako Makgatho University of Medical Science, Pretoria, South Africa.

Maphoshane Nchabeleng (M)

Department of Medical Microbiology and MeCRU, Sefako Makgatho University of Medical Science, Pretoria, South Africa.

Chris Hikuam (C)

South African Tuberculosis Vaccine Initiative, Department of Pathology, Institute of Infectious Disease and Division of Immunology, University of Cape Town, Cape Town, South Africa.

Jerrold J Ellner (JJ)

Department of Medicine, Centre for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, NJ, United States.

Mark Hatherill (M)

South African Tuberculosis Vaccine Initiative, Department of Pathology, Institute of Infectious Disease and Division of Immunology, University of Cape Town, Cape Town, South Africa.

Bernard P Fourie (BP)

Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa.

Mike M Sathekge (MM)

Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa.
Nuclear Medicine Research Infrastructure, Steve Biko Academic Hospital, Pretoria, South Africa.

Classifications MeSH